Summary
• Aclaris Therapeutics (ACRS) shares rose 5% to $2.79 in pre-market following positive clinical trial results.
• Interim Phase 1A trial data for ATI-052 shows potential best-in-class advantages and plans for future trials in 2026.
• The stock has seen high volatility with a 44% quarterly gain, despite a year-to-date decline of 12%.
Aclaris Therapeutics, Inc. (ACRS) is trading at $2.79 in pre-market hours, representing a 5% increase from its last close of $2.65. This uptick is linked to the recent announcement of positive interim results from an important clinical trial.
Clinical Trial Update Fuels Price Jump
Aclaris Therapeutics released promising interim data from its Phase 1A clinical trial of the anti-TSLP/IL-4Rα bispecific antibody ATI-052. The trial’s positive results underscore its potential best-in-class potency advantage and support the possibility of extended dosing intervals, potentially up to every three months. Management has indicated that Phase 1B proof-of-concept trials for atopic dermatitis and asthma are set to begin in the first quarter of 2026, with plans to advance into Phase 2B trials later in the year.
Market Performance Insights
Aclaris has shown significant volatility with a quarterly performance of 44% and a half-year performance of 84%, despite a year-to-date decline of nearly 12%. The stock also carries a relatively stable average trading volume of around 597,508 over the last 10 days, though it has a higher average volume of 1,244,715 over the past three months. The current RSI value of 41.11 indicates that the stock remains near the lower end of the relative strength spectrum, hinting at potential for upward momentum should buying interest sustain.
With the latest update now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session.